octadecanoic acid;[(2R,5S,8R,9S,10S,13S,14S,17S)-2,10,13-trimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] propanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: octadecanoic acid;[(2R,5S,8R,9S,10S,13S,14S,17S)-2,10,13-trimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] propanoate
• 化学式: C41H72O5
• 分子量: 645.0
• InChiKey: VZDOCGGTKMRSIN-FPVXRMKGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.5
• 重原子数：
  46
• 可旋转键数：
  19
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  80.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF
  申请人：Aciex Therapeutics, Inc.

  公开号：EP2941437A1

  公开（公告）日：2015-11-11
• [EN] PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF<br/>[FR] PRÉPARATIONS D'AGENTS THÉRAPEUTIQUES HYDROPHOBES, LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：ACIEX THERAPEUTICS INC

  公开号：WO2014107231A1

  公开（公告）日：2014-07-10

  The present invention further provides method of preparing nanocrystals or microcrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).